The HSF-FLI method was further evaluated in live mouse models bearing HER2+ breast tumor xenografts and treated with FRET-labeled Trastuzumab (TZM), a monoclonal antibody used for HER2-positive breast cancer therapy. The gene discussed is ERBB2; the disease is breast carcinoma.